Tyrosine kinase inhibitor SU6668 inhibits peritoneal dissemination of gastric cancer via suppression of tumor angiogenesis

Jo Tokuyama, Tetsuro Kubota, Yoshiro Saikawa, Masashi Yoshida, Toshiharu Furukawa, Yoshihide Otani, Koichiro Kumai, Masaki Kitajima

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background: Peritoneal dissemination of cancer involves several steps, including tumor cell attachment, invasion and growth in the peritoneum. Tumor angiogenesis is a prerequisite for the growth of disseminated tumor. Vascular endothelial growth factor (VEGF) and its receptor are major regulators of angiogenesis. Purpose: We examined the cytotoxic effects of SU6668, an inhibitor of VEGF tyrosine kinase receptors, on in vitro gastric cancer cell lines and human umbilical vascular endothelial cells (HUVEC); we also examined the antitumor effects of SU6668 on human gastric cancer cells administered intraperitoneally into nude mice. Materials and Methods: Direct cytotoxicity to gastric cancer cells (TMK-1, MKN-45 and MKN-74) and normal cells (HUVEC) was determined by the MTT assay and the bromodeoxyuridine (BrdU) incorporation assay, with and without VEGF-evoked growth stimulation in vitro. TMK-1 cells were transplanted intraperitoneally into nude mice, followed by twice daily oral administration of SU6668 (200 mg/kg/day) for two weeks starting on the first day after transplantation. Both the number and the wet weight of disseminated peritoneal tumor nodules were assessed. Results: In the MTT assay, SU6668 demonstrated low-grade cytotoxicity to the cell growth of three gastric cancer cells, with a 50% inhibitory concentration (IC50) of 22.6 μg/ml for TMK-1, 31.8 μg/ml for MKN-45 and 26.7 μg/ml for MKN-74; HUVEC was sensitive to SU6668 with an IC50 of 8.9 μg/ml. In the BrdU assay, VEGF stimulated DNA synthesis in HUVEC, while the incorporation of BrdU was not affected by VEGF in gastric cancer cell lines. SU6668 inhibited VEGF-induced DNA synthesis in HUVEC, while BrdU incorporation of gastric cancer cell lines was inhibited by SU6668 without correlation to VEGF stimulation. Peritoneal dissemination of cancer in nude mice was significantly suppressed by SU6668 compared with a control group at the p<0.05 level. Conclusion: The mechanism of the antitumor activity of SU6668 may not involve direct toxicity to cancer cells, but may rather be an inhibitory effect on tumor angiogenesis, resulting in the inhibition of tumor dissemination in the peritoneum.

Original languageEnglish
Pages (from-to)17-22
Number of pages6
JournalAnticancer Research
Volume25
Issue number1 A
Publication statusPublished - 2005 Jan

Fingerprint

Protein-Tyrosine Kinases
Stomach Neoplasms
Umbilicus
Vascular Endothelial Growth Factor A
Bromodeoxyuridine
Endothelial Cells
Neoplasms
Nude Mice
Inhibitory Concentration 50
Peritoneum
Growth
Cell Line
orantinib
Vascular Endothelial Growth Factor Receptor
DNA
Receptor Protein-Tyrosine Kinases
Oral Administration
Transplantation
Weights and Measures
Control Groups

Keywords

  • Gastric cancer
  • Peritoneal dissemination
  • SU6668
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tokuyama, J., Kubota, T., Saikawa, Y., Yoshida, M., Furukawa, T., Otani, Y., ... Kitajima, M. (2005). Tyrosine kinase inhibitor SU6668 inhibits peritoneal dissemination of gastric cancer via suppression of tumor angiogenesis. Anticancer Research, 25(1 A), 17-22.

Tyrosine kinase inhibitor SU6668 inhibits peritoneal dissemination of gastric cancer via suppression of tumor angiogenesis. / Tokuyama, Jo; Kubota, Tetsuro; Saikawa, Yoshiro; Yoshida, Masashi; Furukawa, Toshiharu; Otani, Yoshihide; Kumai, Koichiro; Kitajima, Masaki.

In: Anticancer Research, Vol. 25, No. 1 A, 01.2005, p. 17-22.

Research output: Contribution to journalArticle

Tokuyama, J, Kubota, T, Saikawa, Y, Yoshida, M, Furukawa, T, Otani, Y, Kumai, K & Kitajima, M 2005, 'Tyrosine kinase inhibitor SU6668 inhibits peritoneal dissemination of gastric cancer via suppression of tumor angiogenesis', Anticancer Research, vol. 25, no. 1 A, pp. 17-22.
Tokuyama, Jo ; Kubota, Tetsuro ; Saikawa, Yoshiro ; Yoshida, Masashi ; Furukawa, Toshiharu ; Otani, Yoshihide ; Kumai, Koichiro ; Kitajima, Masaki. / Tyrosine kinase inhibitor SU6668 inhibits peritoneal dissemination of gastric cancer via suppression of tumor angiogenesis. In: Anticancer Research. 2005 ; Vol. 25, No. 1 A. pp. 17-22.
@article{f196dc36c7474720939a071d8fbfa24e,
title = "Tyrosine kinase inhibitor SU6668 inhibits peritoneal dissemination of gastric cancer via suppression of tumor angiogenesis",
abstract = "Background: Peritoneal dissemination of cancer involves several steps, including tumor cell attachment, invasion and growth in the peritoneum. Tumor angiogenesis is a prerequisite for the growth of disseminated tumor. Vascular endothelial growth factor (VEGF) and its receptor are major regulators of angiogenesis. Purpose: We examined the cytotoxic effects of SU6668, an inhibitor of VEGF tyrosine kinase receptors, on in vitro gastric cancer cell lines and human umbilical vascular endothelial cells (HUVEC); we also examined the antitumor effects of SU6668 on human gastric cancer cells administered intraperitoneally into nude mice. Materials and Methods: Direct cytotoxicity to gastric cancer cells (TMK-1, MKN-45 and MKN-74) and normal cells (HUVEC) was determined by the MTT assay and the bromodeoxyuridine (BrdU) incorporation assay, with and without VEGF-evoked growth stimulation in vitro. TMK-1 cells were transplanted intraperitoneally into nude mice, followed by twice daily oral administration of SU6668 (200 mg/kg/day) for two weeks starting on the first day after transplantation. Both the number and the wet weight of disseminated peritoneal tumor nodules were assessed. Results: In the MTT assay, SU6668 demonstrated low-grade cytotoxicity to the cell growth of three gastric cancer cells, with a 50{\%} inhibitory concentration (IC50) of 22.6 μg/ml for TMK-1, 31.8 μg/ml for MKN-45 and 26.7 μg/ml for MKN-74; HUVEC was sensitive to SU6668 with an IC50 of 8.9 μg/ml. In the BrdU assay, VEGF stimulated DNA synthesis in HUVEC, while the incorporation of BrdU was not affected by VEGF in gastric cancer cell lines. SU6668 inhibited VEGF-induced DNA synthesis in HUVEC, while BrdU incorporation of gastric cancer cell lines was inhibited by SU6668 without correlation to VEGF stimulation. Peritoneal dissemination of cancer in nude mice was significantly suppressed by SU6668 compared with a control group at the p<0.05 level. Conclusion: The mechanism of the antitumor activity of SU6668 may not involve direct toxicity to cancer cells, but may rather be an inhibitory effect on tumor angiogenesis, resulting in the inhibition of tumor dissemination in the peritoneum.",
keywords = "Gastric cancer, Peritoneal dissemination, SU6668, Vascular endothelial growth factor",
author = "Jo Tokuyama and Tetsuro Kubota and Yoshiro Saikawa and Masashi Yoshida and Toshiharu Furukawa and Yoshihide Otani and Koichiro Kumai and Masaki Kitajima",
year = "2005",
month = "1",
language = "English",
volume = "25",
pages = "17--22",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1 A",

}

TY - JOUR

T1 - Tyrosine kinase inhibitor SU6668 inhibits peritoneal dissemination of gastric cancer via suppression of tumor angiogenesis

AU - Tokuyama, Jo

AU - Kubota, Tetsuro

AU - Saikawa, Yoshiro

AU - Yoshida, Masashi

AU - Furukawa, Toshiharu

AU - Otani, Yoshihide

AU - Kumai, Koichiro

AU - Kitajima, Masaki

PY - 2005/1

Y1 - 2005/1

N2 - Background: Peritoneal dissemination of cancer involves several steps, including tumor cell attachment, invasion and growth in the peritoneum. Tumor angiogenesis is a prerequisite for the growth of disseminated tumor. Vascular endothelial growth factor (VEGF) and its receptor are major regulators of angiogenesis. Purpose: We examined the cytotoxic effects of SU6668, an inhibitor of VEGF tyrosine kinase receptors, on in vitro gastric cancer cell lines and human umbilical vascular endothelial cells (HUVEC); we also examined the antitumor effects of SU6668 on human gastric cancer cells administered intraperitoneally into nude mice. Materials and Methods: Direct cytotoxicity to gastric cancer cells (TMK-1, MKN-45 and MKN-74) and normal cells (HUVEC) was determined by the MTT assay and the bromodeoxyuridine (BrdU) incorporation assay, with and without VEGF-evoked growth stimulation in vitro. TMK-1 cells were transplanted intraperitoneally into nude mice, followed by twice daily oral administration of SU6668 (200 mg/kg/day) for two weeks starting on the first day after transplantation. Both the number and the wet weight of disseminated peritoneal tumor nodules were assessed. Results: In the MTT assay, SU6668 demonstrated low-grade cytotoxicity to the cell growth of three gastric cancer cells, with a 50% inhibitory concentration (IC50) of 22.6 μg/ml for TMK-1, 31.8 μg/ml for MKN-45 and 26.7 μg/ml for MKN-74; HUVEC was sensitive to SU6668 with an IC50 of 8.9 μg/ml. In the BrdU assay, VEGF stimulated DNA synthesis in HUVEC, while the incorporation of BrdU was not affected by VEGF in gastric cancer cell lines. SU6668 inhibited VEGF-induced DNA synthesis in HUVEC, while BrdU incorporation of gastric cancer cell lines was inhibited by SU6668 without correlation to VEGF stimulation. Peritoneal dissemination of cancer in nude mice was significantly suppressed by SU6668 compared with a control group at the p<0.05 level. Conclusion: The mechanism of the antitumor activity of SU6668 may not involve direct toxicity to cancer cells, but may rather be an inhibitory effect on tumor angiogenesis, resulting in the inhibition of tumor dissemination in the peritoneum.

AB - Background: Peritoneal dissemination of cancer involves several steps, including tumor cell attachment, invasion and growth in the peritoneum. Tumor angiogenesis is a prerequisite for the growth of disseminated tumor. Vascular endothelial growth factor (VEGF) and its receptor are major regulators of angiogenesis. Purpose: We examined the cytotoxic effects of SU6668, an inhibitor of VEGF tyrosine kinase receptors, on in vitro gastric cancer cell lines and human umbilical vascular endothelial cells (HUVEC); we also examined the antitumor effects of SU6668 on human gastric cancer cells administered intraperitoneally into nude mice. Materials and Methods: Direct cytotoxicity to gastric cancer cells (TMK-1, MKN-45 and MKN-74) and normal cells (HUVEC) was determined by the MTT assay and the bromodeoxyuridine (BrdU) incorporation assay, with and without VEGF-evoked growth stimulation in vitro. TMK-1 cells were transplanted intraperitoneally into nude mice, followed by twice daily oral administration of SU6668 (200 mg/kg/day) for two weeks starting on the first day after transplantation. Both the number and the wet weight of disseminated peritoneal tumor nodules were assessed. Results: In the MTT assay, SU6668 demonstrated low-grade cytotoxicity to the cell growth of three gastric cancer cells, with a 50% inhibitory concentration (IC50) of 22.6 μg/ml for TMK-1, 31.8 μg/ml for MKN-45 and 26.7 μg/ml for MKN-74; HUVEC was sensitive to SU6668 with an IC50 of 8.9 μg/ml. In the BrdU assay, VEGF stimulated DNA synthesis in HUVEC, while the incorporation of BrdU was not affected by VEGF in gastric cancer cell lines. SU6668 inhibited VEGF-induced DNA synthesis in HUVEC, while BrdU incorporation of gastric cancer cell lines was inhibited by SU6668 without correlation to VEGF stimulation. Peritoneal dissemination of cancer in nude mice was significantly suppressed by SU6668 compared with a control group at the p<0.05 level. Conclusion: The mechanism of the antitumor activity of SU6668 may not involve direct toxicity to cancer cells, but may rather be an inhibitory effect on tumor angiogenesis, resulting in the inhibition of tumor dissemination in the peritoneum.

KW - Gastric cancer

KW - Peritoneal dissemination

KW - SU6668

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=16344369880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16344369880&partnerID=8YFLogxK

M3 - Article

C2 - 15816514

AN - SCOPUS:16344369880

VL - 25

SP - 17

EP - 22

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1 A

ER -